Biogen Notes Progress With Alzheimer’s Drug
Currently, there is an ongoing study for the drug for Alzheimer’s that is being undertaken by Biogen Idec Inc. They are saying that there has been a positive result so far, which has not only shot the shares for the company skyrocketing but has also reopened the debate about drugs that are used to attack buildups of amyloid plaque located in the brain.
The study has 200 participants who all are in the early stages of the disease and the patients are either getting the drug or a placebo. The patients have undergone roughly 54 weeks of the treatment and so far the results are showing a reduced level of the amyloid in the brain and a significant positive effect on the cognition of the individuals.
The study results will be released in full at an undisclosed medical conference sometime during 2015, but they wanted to announce that the study is having positive effects on the disease. Researchers had said that they were interested in the results but wanted to see the full data from the trial.